Loading...
Swedish Orphan Biovitrum AB (publ)
BIOVF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$29.79
$0.00(0.00%)
Swedish Orphan Biovitrum AB (publ) (BIOVF) Financial Performance & Income Statement Overview
Review Swedish Orphan Biovitrum AB (publ)’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
17.65%
↑ 17.65%
Operating Income Growth
38.34%
↑ 38.34%
Net Income Growth
61.27%
↑ 61.27%
Operating Cash Flow Growth
65.28%
↑ 65.28%
Operating Margin
21.72%
↑ 21.72%
Gross Margin
74.58%
↑ 74.58%
Net Profit Margin
15.09%
↑ 15.09%
ROE
10.37%
↑ 10.37%
ROIC
9.80%
↑ 9.80%
Swedish Orphan Biovitrum AB (publ) (BIOVF) Income Statement & Financial Overview
Review Swedish Orphan Biovitrum AB (publ)'s (BIOVF) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $6.46B | $7.44B | $6.89B | $5.44B |
| Cost of Revenue | $1.50B | $1.60B | $1.33B | $2.15B |
| Gross Profit | $4.97B | $5.84B | $5.56B | $3.29B |
| Gross Profit Ratio | $0.77 | $0.78 | $0.81 | $0.61 |
| R&D Expenses | $834.00M | $981.00M | $845.00M | $898.00M |
| SG&A Expenses | $2.68B | $3.19B | $1.81B | $1.75B |
| Operating Expenses | $3.61B | $4.17B | $3.52B | $2.65B |
| Total Costs & Expenses | $5.11B | $5.77B | $4.86B | $4.80B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $326.00M | $337.00M |
| Depreciation & Amortization | $938.00M | $932.00M | $924.00M | $915.00M |
| EBITDA | $2.29B | $2.59B | $2.96B | $1.55B |
| EBITDA Ratio | $0.35 | $0.35 | $0.43 | $0.29 |
| Operating Income | $1.36B | $1.66B | $2.04B | $640.00M |
| Operating Income Ratio | $0.21 | $0.22 | $0.30 | $0.12 |
| Other Income/Expenses (Net) | -$262.00M | -$225.00M | -$326.00M | -$337.00M |
| Income Before Tax | $1.10B | $1.44B | $1.71B | $275.00M |
| Income Before Tax Ratio | $0.17 | $0.19 | $0.25 | $0.05 |
| Income Tax Expense | $221.00M | $47.00M | $248.00M | $51.00M |
| Net Income | $875.00M | $1.40B | $1.46B | $224.00M |
| Net Income Ratio | $0.14 | $0.19 | $0.21 | $0.04 |
| EPS | $2.55 | $4.07 | $4.27 | $0.66 |
| Diluted EPS | $2.52 | $4.03 | $4.22 | $0.65 |
| Weighted Avg Shares Outstanding | $343.45M | $343.23M | $343.01M | $340.59M |
| Weighted Avg Shares Outstanding (Diluted) | $346.97M | $347.06M | $346.84M | $344.75M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan